GH Research
GHRS27.7501.72% ( +0.470 )
GH Research (GHRS)
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States....
- Open
- 27.860
- High
- 29.050
- Low
- 27.150
- Prev. Close
- 27.280
- Volume
- 279.93K
- Turnover
- 7.83M
- Avg Price
- 27.962
- Bid/Ask Ratio
- --
- Amplitude
- 6.96%
- 52wk High
- 31.000
- Volume Ratio
- 1.71
- Turnover Ratio
- 0.95%
GH Research Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$40.0044.14%
Forecast & RatingStrong buy
10analysts
- Strong buy70.00%
- Buy30.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 24 at 04:13 AM
Global capital pivots to idiosyncratic U.S. assets as macro headwinds intensify
- Global Report · Jul 22 at 04:18 AM
Q1 2026 Overhauls: Strategic Pivots Across Retail, Energy, and Niche Tech
- Global Report · Jul 19 at 04:13 AM
Capital in the Crevices: What the Market's Long Tail Tells Us About 2026
- Global Report · Jul 18 at 04:12 AM
Tech and Biotech Sectors See Specialized Consolidation Amid 2026 Regulatory Milestones
- benzinga_article · Jul 16 at 11:36 AM
Why Is GH Research Stock Trading Higher on Thursday?
- StockTitan · Jul 15 at 09:45 PM
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions | LLY Stock News
